Codiak BioSciences

51 articles with Codiak BioSciences

• Codiak BioSciences Expands Executive Leadership

  6/15/2021

  Codiak BioSciences, Inc. today announced the promotion of Sriram Sathyanarayanan, Ph.D.

• Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

  6/2/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. Details are as follows:

• Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

  5/20/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.

• 

  BioSpace Movers & Shakers, May 14

  5/14/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.

• New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

  5/11/2021

  Data at ASGCT 2021 show ability to design exosomes with specific features for immune evasion, tunable vaccine development, targeted cell tropism and potent target engagement

• Codiak Appoints Jennifer Wheler, M.D., as Chief Medical Officer

  5/10/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of Jennifer Wheler, M.D.

• Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress

  5/6/2021

  Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year

• Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

  4/27/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that the company will present data from its engEx™ Platform at the 24th Annual Meeting of the American Society of Gene and Cell Therapy, which is being held virtually from May 11-14, 2021.

• Data from Codiak’s exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology

  4/22/2021

  Codiak BioSciences, Inc., a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced the online publication of a new manuscript, exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance, in Communications Biology, a Nature Research publication.

• Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways

  4/10/2021

  exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021

• Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

  3/17/2021

  – First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients – – On track to report biomarker, safety and clinical anti-tumor efficacy results in cancer patients in mid-2021 for exoSTING™ and by year-end for exoIL-12 –

• Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting

  3/10/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the company will present data from two of its programs evaluating engineered exosome therapeutic candidates for the treatment of cancer at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

• Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option

  2/17/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,162,500 shares of its common stock at a public offering price of $21.00 per share

• Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock

  2/12/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share, for gross proceeds of approximately $57.8 million, before deducting underwriting discounts and commissions and offering expenses.

• Codiak Announces Proposed Public Offering of Common Stock

  2/9/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today that it has commenced an underwritten public offering of 2,500,000 shares of its common stock.

• Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients

  2/4/2021

  – Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity without systemic IL-12 exposure – – Plan to initiate multi-dose study in CTCL patients, with data anticipated by year-end 2021–

• Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

  1/21/2021

  New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties

• Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers

  12/30/2020

  – exoIL-12 resulted in no local or systemic treatment-related adverse events – – Local administration of exoIL-12 demonstrated no systemic exposure to IL-12 – – Dose selection data and advancement into multi-dose study in cutaneous T cell lymphoma patients anticipated in Q1 2021 –

• New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of Cancer

  12/21/2020

  Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared to recombinant IL-12, in Molecular Cancer Therapeutics,

• Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

  11/23/2020

  Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference.